The United Laboratories International Holdings Limited (3933.HK)

HKD 11.34

(-1.05%)

Market Cap (In HKD)

20.6 Billion

Revenue (In HKD)

13.73 Billion

Net Income (In HKD)

2.7 Billion

Avg. Volume

3.73 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.52-12.12
PE
-
EPS
-
Beta Value
0.058
ISIN
KYG8813K1085
CUSIP
G8813K108
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Hoi Shan Tsoi
Employee Count
-
Website
https://www.tul.com.cn
Ipo Date
2007-06-15
Details
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, distribution, and sale of pharmaceutical products. It operates through three segments: Bulk Medicine, Intermediate Products, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings; holds trademarks; and trades in pharmaceutical products. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong.